NewsRx

Search our medical news database

Biotechnology

Spherix Reports Second Quarter 2009 Earnings

Published in Healthcare Mergers, Acquisitions and Ventures Week, September 5th, 2009

Spherix Incorporated (NASDAQ:SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, reported results for the second quarter ended June 30, 2009. Recent and Upcoming Company Highlights -- Biospherics Subsidiary

-- Clinical trials on Naturlose (D-tagatose) as a treatment for Type

Keywords: Biotechnology, Diabetes, Pharmaceuticals, Therapy, Treatment, Spherix Incorporated.

This article was prepared by Healthcare Mergers, Acquisitions & Ventures Week editors from staff and other reports. Copyright...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook